Company intelligence / Profile preview

CorMedix

Berkeley Heights, New Jersey, USAzoominfo.com ↗

Ownership: Private
Development stage: Commercial

Overview

CorMedix’s lead product DefenCath (taurolidine and heparin) demonstrated a 71% reduction in infection risk for dialysis patients. The drug received FDA approval in November 2023 and was commercially launched in the U.S. during 2024

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeCombination product (taurolidine and heparin)
Industry: Biotech

Beyond the preview

Go deeper on CorMedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CorMedix.

Explore the full profile